Tromsø, April 19 2022 - ArcticZymes Technologies ASA (OSE: AZT) announces it has
signed a new agreement with a large international Life Science company.

ArcticZymes Technologies has signed an original equipment manufacturing (OEM)
agreement with a renowned and leading international Life Science company. The
undisclosed partner will incorporate several of ArcticZymesŽ enzymes into their
extensive and synergistic portfolio. The partnership indirectly extends
ArcticZymesŽ commercial reach towards In Vitro Diagnostics (IVD) and
bioprocessing development organizations.  Such partnerships are integral to
ArcticZymesŽ commercial strategy to expand commercial presence and awareness
throughout the industry via direct and indirect representation.

The partner is a global Life Science tools and solution provider with a
workforce of more than 20,000 employees. ArcticZymesŽ enzymes complement gaps in
our partners portfolio to enable its customers with best-in-class technologies.

The agreement is a mutual starting point to build a long-term strategic
partnership with the prospect to extend activities through other existing
enzymes and new pipeline developments.

ArcticZymes Technologies ASA, CEO, Jethro Holter said:

"ArcticZymes is delighted to announce the new strategic partnership via this OEM
agreement. We are proud to partner with leading Life Science companies to gain
greater market relevance of our technologies."

For more information, please contact:

ArcticZymes Technologies
CEO, Jethro Holter        Tel: +47 46 85 91 46
CFO, Børge Sørvoll        Tel: +47 95 29 01 87
                            ir@arcticzymes.com

About ArcticZymes Technologies ASA

ArcticZymes Technologies is a Norwegian life sciences company focused on the
development, manufacturing and commercialization of novel recombinant enzymes
for use in molecular research, In Vitro Diagnostics (IVD) and biomanufacturing.

Listed on the Oslo Stock Exchange since 2005 originally under the [Biotec]
ticker, as Biotec Pharmacon. The company rebranded as ArcticZymes Technologies
in 2020 under the [AZT] ticker. Its headquarters are based in Tromsø, Norway, at
the SIVA Innovation Centre.

ArcticZymes Technologies' IP and capabilities are protected via a large
portfolio of patents.

For more information, please visit the website: www.arcticzymes.com.